LUCD vs. CTSO, AMIX, NSPR, APYX, DRIO, ICCM, XAIR, DXR, HSAQ, and GBS
Should you be buying Lucid Diagnostics stock or one of its competitors? The main competitors of Lucid Diagnostics include Cytosorbents (CTSO), Autonomix Medical (AMIX), InspireMD (NSPR), Apyx Medical (APYX), DarioHealth (DRIO), IceCure Medical (ICCM), Beyond Air (XAIR), Daxor (DXR), Health Sciences Acquisitions Co. 2 (HSAQ), and GBS (GBS). These companies are all part of the "surgical & medical instruments" industry.
Lucid Diagnostics (NASDAQ:LUCD) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.
Cytosorbents received 409 more outperform votes than Lucid Diagnostics when rated by MarketBeat users. Likewise, 79.38% of users gave Cytosorbents an outperform vote while only 60.47% of users gave Lucid Diagnostics an outperform vote.
Cytosorbents has a net margin of -75.07% compared to Lucid Diagnostics' net margin of -2,169.07%. Cytosorbents' return on equity of -129.89% beat Lucid Diagnostics' return on equity.
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 4.8% of Lucid Diagnostics shares are owned by insiders. Comparatively, 6.6% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 10 articles in the media. Cytosorbents' average media sentiment score of 0.39 beat Lucid Diagnostics' score of -0.17 indicating that Cytosorbents is being referred to more favorably in the news media.
Lucid Diagnostics has a beta of 1.48, suggesting that its stock price is 48% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.
Cytosorbents has higher revenue and earnings than Lucid Diagnostics. Cytosorbents is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Lucid Diagnostics currently has a consensus price target of $2.75, indicating a potential upside of 189.47%. Cytosorbents has a consensus price target of $2.50, indicating a potential upside of 199.47%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Lucid Diagnostics.
Summary
Cytosorbents beats Lucid Diagnostics on 11 of the 17 factors compared between the two stocks.
Get Lucid Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lucid Diagnostics Competitors List
Related Companies and Tools
